Ghrelin Relieves Cancer Bone Pain by Triggering Hypothalamic NPY Production Through AMPK-mTOR
Ghrelin administration alleviated cancer-induced bone pain in rats by activating the AMPK-mTOR pathway in the hypothalamus to increase NPY production, which exerted pain relief through Y1 and Y2 receptors.
Quick Facts
What This Study Found
Ghrelin activated the hypothalamic AMPK-mTOR pathway to induce NPY production, alleviating cancer-induced bone pain in rats. NPY's antinociceptive effect was mediated through Y1 and Y2 receptors and reversed by GHS-R1α antagonism.
Key Numbers
CIBP mouse model with exogenous NPY administration and NPY receptor antagonist testing. AMPK-mTOR pathway confirmed as mediator.
How They Did This
Cancer-induced bone pain model established in rats. Intracerebroventricular administration of NPY, NPY receptor antagonists (Y1R, Y2R), and ghrelin. Measured body weight, food intake, behavioral pain indicators, and hypothalamic ghrelin, NPY, and AMPK-mTOR pathway markers.
Why This Research Matters
Cancer bone pain is often inadequately controlled with existing analgesics. Discovering that ghrelin and NPY — naturally occurring peptides — can modulate this specific type of pain through a defined brain pathway opens entirely new therapeutic approaches.
The Bigger Picture
Cancer pain management remains a major unmet need, with opioids carrying addiction risks and limited efficacy for bone pain. Peptide-based approaches targeting the brain's own pain regulation systems could provide alternatives or complementary therapies with potentially fewer side effects than opioids.
What This Study Doesn't Tell Us
Animal study using an intracerebroventricular injection route, which isn't practical for clinical use. The short-term nature of NPY's pain relief may limit standalone therapeutic utility. Translation from rat brain to human brain pain processing is uncertain.
Questions This Raises
- ?Could systemic ghrelin administration (rather than brain injection) provide enough hypothalamic NPY stimulation to relieve cancer bone pain?
- ?Would ghrelin agonists already in clinical development for other indications show pain-relieving effects in cancer patients?
- ?How does this ghrelin-NPY pain pathway interact with opioid-based pain management?
Trust & Context
- Key Stat:
- Ghrelin → NPY pain relief A novel non-opioid pathway where ghrelin stimulates hypothalamic NPY production through AMPK-mTOR to alleviate cancer bone pain
- Evidence Grade:
- Preliminary evidence from a single animal study with intracerebroventricular peptide administration. The mechanistic pathway is well-characterized but has no human clinical data.
- Study Age:
- Published in 2024; represents emerging research on peptide-mediated cancer pain management.
- Original Title:
- Ghrelin Induces the Production of Hypothalamic NPY Through the AMPK-mTOR Pathway to Alleviate Cancer-induced Bone Pain.
- Published In:
- In vivo (Athens, Greece), 38(3), 1133-1142 (2024)
- Authors:
- Xu, Longjie, Hou, Lili, Cao, Chun, Li, Xiaohua
- Database ID:
- RPEP-09567
Evidence Hierarchy
Frequently Asked Questions
What is cancer-induced bone pain and why is it so hard to treat?
When cancer spreads to bones, it causes severe, persistent pain that is often poorly controlled by standard painkillers. Bone metastasis pain involves complex mechanisms including nerve damage, inflammation, and bone destruction, making it one of the most challenging types of cancer pain to manage.
Could ghrelin be used as a pain medication?
Not yet — this study used direct brain injection, which isn't practical for patients. However, ghrelin and ghrelin-like drugs are already being studied for other conditions (appetite, muscle wasting). If the pain-relieving effects can be achieved with systemic administration, it could open a new approach to cancer pain management.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09567APA
Xu, Longjie; Hou, Lili; Cao, Chun; Li, Xiaohua. (2024). Ghrelin Induces the Production of Hypothalamic NPY Through the AMPK-mTOR Pathway to Alleviate Cancer-induced Bone Pain.. In vivo (Athens, Greece), 38(3), 1133-1142. https://doi.org/10.21873/invivo.13548
MLA
Xu, Longjie, et al. "Ghrelin Induces the Production of Hypothalamic NPY Through the AMPK-mTOR Pathway to Alleviate Cancer-induced Bone Pain.." In vivo (Athens, 2024. https://doi.org/10.21873/invivo.13548
RethinkPeptides
RethinkPeptides Research Database. "Ghrelin Induces the Production of Hypothalamic NPY Through t..." RPEP-09567. Retrieved from https://rethinkpeptides.com/research/xu-2024-ghrelin-induces-the-production
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.